- MedMira (MIR) has announced the receipt of a U.S. patent (number 11,353,450) for its innovative and quantitative test system
- With this new patent, MedMira will further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology(RVF)-based diagnostic tests
- This is a boost to MedMira’s multiplexed quantitative diagnostic system
- The company will provide in the coming months the launch plan and next steps
- MedMira is a leading developer and manufacturer of Rapid Vertical Flow diagnostics
- MedMira Inc. opened trading at $0.13
MedMira (MIR) has received a U.S. patent (number 11,353,450) for its innovative and quantitative test system.
With this new patent, MedMira will further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology (RVF)-based diagnostic tests.
This is a boost to the company’s vision by offering a rapid multiplexed quantitative diagnostic system from screening to confirmation to monitoring disease progression.
The synergies between both patented technologies allow MedMira to continue its corporate aim to provide the market with a highly effective and affordable alternative to the current costly and time-consuming screening and monitoring systems.
“Our RVF Technology-based rapid test provides an immediate quality Yes or No answer enabling health care providers to diagnose specific marker(s) at a true Point-of-Care situation,” noted Hermes Chan, CEO of MedMira Inc.
“We strongly believe in the value of such affordable and easy-to-use testing methods, which the world has clearly seen with the COVID-19 pandemic,” he added.
MedMira’s latest novel diagnostic system allows for accessible and efficient diagnostic tools for quantitative results in minutes. The user-friendly interface combined with automated interpretation allows for an expansion of MedMira’s current RVF-based tests and can provide a pathway to significantly increase the technology’s multiplexing abilities.
The combination of the RVF and Surface-Enhanced Raman Spectroscopy (SERS) technology, creates MedMira’s patented novel high quality and cost-effective tool for the next generation – MIROQ.
The company developed the first prototype system in 2014 and went through extensive verification and validation performed by its academic partners in Nova Scotia.
MedMira will provide in the coming months the launch plan and next steps.
MedMira is a leading developer and manufacturer of Rapid Vertical Flow diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps.
MedMira Inc. opened trading at $0.13.
